Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KHK | P50053 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30711985 | 1.00 | SMN1; SMN2 (0.64) | SMN1; SMN2KDM4EGAAPKMPOLB | |
| SCHEMBL29618412 | 0.78 | SMN1; SMN2 (1.00) | SMN1; SMN2KDM4EGAAMAPK1ALDH1A1 | |
| SCHEMBL16019318 | 0.78 | SMN1; SMN2 (0.93) | SMN1; SMN2KDM4EGAAPKMMAPK1 | |
| SCHEMBL29375167 | 0.78 | SMN1; SMN2 (0.93) | SMN1; SMN2KDM4EGAAPKMMAPK1 | |
| SCHEMBL5624979 | 0.78 | SMN1; SMN2 (1.00) | SMN1; SMN2KDM4EGAAMAPK1ALDH1A1 | |
| SCHEMBL7913275 | 0.77 | SMN1; SMN2 (0.97) | SMN1; SMN2KDM4EGAAMAPK1ALDH1A1 | |
| SCHEMBL29618403 | 0.75 | SMN1; SMN2 (0.53) | SMN1; SMN2KDM4EGAAPKMPOLB | |
| SCHEMBL28758443 | 0.75 | SMN1; SMN2 (0.53) | SMN1; SMN2KDM4EGAAPKMPOLB | |
| SCHEMBL4086101 | 0.73 | SMN1; SMN2 (0.39) | SMN1; SMN2KDM4EGAAPKMPOLB | |
| SCHEMBL17985355 | 0.73 | SMN1; SMN2 (0.62) | SMN1; SMN2KDM4EGAAPKMPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12508268-B2 | Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2025-12-30 | — | — | US | disclosed |
| US-20240285641-A1 | INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2024-08-29 | — | — | US | disclosed |
| CN-117618423-A | Inhibitors of tryptophan dioxygenase (IDO 1 and TDO) and their use in therapy | 奥克兰联合服务有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-117599049-A | Inhibitors of tryptophan dioxygenase (IDO 1 and TDO) and their use in therapy | 奥克兰联合服务有限公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-110869363-B | 5-membered and bicyclic heterocyclic amides as ROCK inhibitors | 百时美施贵宝公司 | 2024-01-05 | — | — | CN | disclosed |
| US-11826316-B2 | Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2023-11-28 | — | — | US | disclosed |
| US-11673886-B2 | 5-membered and bicyclic heterocyclic amides as inhibitors of ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-06-13 | — | — | US | disclosed |
| US-20220356179-A1 | 5-MEMBERED AND BICYCLIC HETEROCYCLIC AMIDES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2022-11-10 | — | — | US | disclosed |
| EP-3180002-B1 | INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 AND TDO) AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LTD (NZ) | 2022-04-20 | — | — | EP | disclosed |
| US-11078197-B2 | 5-membered and bicyclic heterocyclic amides as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-08-03 | — | — | US | disclosed |
| WO-2016024233-A1 | INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 AND TDO) AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-02-18 | — | — | WO | disclosed |
| US-9249135-B2 | Therapeutic agent for mood disorders | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2016-02-02 | — | — | US | disclosed |
| US-20150225417-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | KYOWA KIRIN CO., LTD. (JP) | 2015-08-13 | — | — | US | disclosed |
| US-20150080415-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | KYOWA KIRIN CO., LTD. (JP) | 2015-03-19 | — | — | US | disclosed |
| US-20120184554-A1 | THERAPEUTIC AGENT FOR MOOD DISORDERS | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-07-19 | — | — | US | disclosed |
| EP-2474544-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | Kyowa Hakko Kirin Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
| EP-2474543-A1 | THERAPEUTIC AGENT FOR MOOD DISORDERS | Kyowa Hakko Kirin Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20120172362-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-07-05 | — | — | US | disclosed |
| US-20120101101-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-04-26 | — | — | US | disclosed |
| EP-2433938-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | Kyowa Hakko Kirin Co., Ltd. (JP) | 2012-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673886-B2 | 5-membered and bicyclic heterocyclic amides as inhibitors of ROCK | MYLK, ROCK1, ROCK2 | SMN1; SMN2 990/4885KDM4E 507/4885GAA 4201/4885 |
| US-11826316-B2 | Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy | IDO1, TDO2, IDO2 | SMN1; SMN2 3658/4885KDM4E 768/4885GAA 2320/4885 |
| US-20240285641-A1 | INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY | IDO1, TDO2, IDO2 | SMN1; SMN2 3658/4885KDM4E 768/4885GAA 2320/4885 |
| US-20120184554-A1 | THERAPEUTIC AGENT FOR MOOD DISORDERS | TPH1, HDAC1, HDAC2 | SMN1; SMN2 4025/4885KDM4E 2195/4885GAA 1505/4885 |
| US-12508268-B2 | Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy | IDO1, IDO2, TDO2 | SMN1; SMN2 3177/4885KDM4E 1473/4885GAA 3436/4885 |
| US-11078197-B2 | 5-membered and bicyclic heterocyclic amides as inhibitors of rock | MYLK, ROCK1, ROCK2 | SMN1; SMN2 1015/4885KDM4E 534/4885GAA 4198/4885 |
| US-20220356179-A1 | 5-MEMBERED AND BICYCLIC HETEROCYCLIC AMIDES AS INHIBITORS OF ROCK | MYLK, ROCK1, ROCK2 | SMN1; SMN2 990/4885KDM4E 507/4885GAA 4201/4885 |
| US-20120172362-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | TAAR1, SLC6A1, GABBR1 | SMN1; SMN2 3241/4885KDM4E 3799/4885GAA 1294/4885 |
| US-20120101101-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | DDT, COMT, SLC6A3 | SMN1; SMN2 81/4885KDM4E 4721/4885GAA 37/4885 |
| US-20150080415-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | TAAR1, SLC6A1, GABBR1 | SMN1; SMN2 3241/4885KDM4E 3799/4885GAA 1294/4885 |
| US-20150225417-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | DDT, COMT, SLC6A3 | SMN1; SMN2 81/4885KDM4E 4721/4885GAA 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.